title: Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration.
abstract: OBJECTIVE
  To compare the functional and morphological response to the initial intravitreal (IVT) injection of bevacizumab in exudative age-related macular degeneration (AMD) patients with the complement factor H (CFH) gene polymorphism T1277C in the Brazilian population.
  
  
  METHODS
  Twenty-five unrelated patients with treatment-naive exudative AMD underwent an IVT injection of 1.25 mg bevacizumab at the initial presentation (D0) and were reexamined 7 days (D7) and 28 days (D28) later. The time and extent of visual acuity (VA) and central retinal thickness (CRT) changes were evaluated according to the presence of the T1277C polymorphism.
  
  
  RESULTS
  In the homozygous risk group (CC), VA improvement was detected mostly from D7 to D28, while in the heterozygous (CT) and homozygous for the wild-type allele (TT) groups, functional response occurred earlier, from D0 to D7. Morphological response to the first IVT injection of bevacizumab was significant in the CT and TT groups, while the CC group presented no significant change in CRT up to D28.
  
  
  CONCLUSIONS
  The CC variant of the CFH gene polymorphism T1277C is related to delayed functional and limited morphological response to the initial IVT injection of bevacizumab in exudative AMD patients in a sample of the Brazilian population.
authors.affiliation: UNICAMP - Universidade de Campinas, Campinas, Brazil.
authors.forename: Flavio Mac Cord
authors.initials: FM
authors.lastname: Medina
authors.forename: Augusto
authors.initials: A
authors.lastname: Alves Lopes da Motta
authors.forename: Walter Y
authors.initials: WY
authors.lastname: Takahashi
authors.forename: Pedro Carlos
authors.initials: PC
authors.lastname: Carricondo
authors.forename: Mario Martins
authors.initials: MM
authors.lastname: Dos Santos Motta
authors.forename: Monica B
authors.initials: MB
authors.lastname: Melo
authors.forename: Jose Paulo C
authors.initials: JP
authors.lastname: Vasconcellos
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D017242:Complement Factor H / Q000235:genetics; D005260:Female; D060005:Genotyping Techniques; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D010597:Pharmacogenetics; D010865:Pilot Projects; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; C493495:CFH protein, human; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D017242:Complement Factor H